亚洲依依成人综合网站,手机看片国内基地,日本性爱视频大全在线观看,秋水一色性福利导航,欧美A级V片在线观看,韩国论理片,欧美特色AAA大片,6一12泑女WWW,肥臀喷水上位

產品中心

Product center

AZD8055 98%

(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol

源葉(MedMol)
S80013
1009298-09-2
C25H31N5O4
465.56
品牌 貨號 產品規格 價格(RMB) 庫存(上海) 北京 武漢 南京 購買數量
源葉(MedMol) S80013-5mg 98% ¥183.60元 >10 - - -
源葉(MedMol) S80013-10mg 98% ¥204.00元 >10 - - -
源葉(MedMol) S80013-25mg 98% ¥476.00元 >10 - - -
源葉(MedMol) S80013-50mg 98% ¥612.00元 >10 - - -
源葉(MedMol) S80013-100mg 98% ¥1070.00元 >10 - - -
源葉(MedMol) S80013-200mg 98% ¥1632.00元 7 - - -
產品介紹 參考文獻 質檢證書(COA) 摩爾濃度計算器 相關產品

產品介紹

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2
產品描述: AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2
靶點: mTOR:0.8 nM (IC50);mTORC1;mTORC2;Autophagy;Apoptosis;mTOR;Autophagy
體內研究:
In mice bearing U87-MG (PTEN null) glioblastoma xenografts, oral treatment with AZD-8055 (AZD8055) results in a dose-dependent tumor growth inhibition of 33%, 48%, and 77% with 2.5, 5, and 10 mg/kg/d twice daily, respectively. A similar dose dependency is observed in nude mice bearing A549 xenografts: tumor growth inhibition is 44%, 55%, and 93% after 2.5, 5, and 10 mg/kg/d twice daily, respectively. AZD8055 also results in significant inhibition of tumor growth and/or regression in breast, lung, colon, prostate, and uterine xenograft models when administered either twice daily at 10 mg/kg or daily at a dose of 20 mg/kg. AZD8055 markedly decreases the phosphorylation levels of mTOR and its substrates and the activation of microglia in vivo, and promotes the microglial polarization from M1 phenotype to M2 phenotype. In addition, administration of AZD8055 following subarachnoid hemorrhage (SAH) significantly ameliorates EBI, including neuronal apoptosis, neuronal necrosis, brain edema and blood-brain barrier permeability
參考文獻:
1. Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298.2. You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31. 3. Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.
溶解性: DMSO  :  33.33  mg/mL  (71.59  mM;  Need  ultrasonic)
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.148 ml 10.74 ml 21.48 ml
5 mM 0.43 ml 2.148 ml 4.296 ml
10 mM 0.215 ml 1.074 ml 2.148 ml
50 mM 0.043 ml 0.215 ml 0.43 ml
注意: 部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。

參考文獻

質檢證書(COA)

如何獲取質檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:C10000001 貨號:A800001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關產品